Identification and Analysis of Components in Yizhi Granule and Cynomolgus Monkey Plasma after Oral Administration by UPLC/ESI-Q-TOF MS and Their Protective Effects on PC12 Cells

Figure 10

Screening of the components with a protective effect on PC12 treated with Aβ25-35. Samples are as follows: 1, blank control group; 2, model control group; 3, YZG group; 4, galantamine hydrobromide group; 5, berberine hydrochloride group; 6, ginsenoside Rb1 group; 7, ginsenoside Rb2 group; 8, ginsenoside Rb3 group; 9, ginsenoside Rc group; 10, ginsenoside Rd group; 11, ginsenoside Re group; 12, ginsenoside Rf group; 13, ginsenoside Rg1 group; 14, ginsenoside Rg2 group; 15, notoginsenoside Fa group; 16, notoginsenoside R1 group; 17, notoginsenoside R2 group; 18, gypenoside A group; and 19, gypenoside XLIX group.